ASAditya Sardesai

Aditya Sardesai

*This is an algorithmically generated author record based on publicly available information.

Aditya Sardesai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes

    by Alexia Kieffer, Matthieu Beuvelet, Gerald Moncayo, Mersha Chetty, Aditya Sardesai, Robert Musci, Richard Hudson

    Introduction Respiratory syncytial virus (RSV) leads to significant morbidity in newborn infants in the United Kingdom (UK). Nirsevimab, a long-acting monoclonal antibody, received approval from the European Medicines Agency and has been licensed by the Medicines and Healthcare products Regulatory Agency for preventing RSV lower respiratory tract disease (LRTD) in neonates and infants during their first RSV season. The objective of this study was to assess the potential impact of nirsevimab on RSV-associated LRTDs, related costs, and loss of quality-adjusted life years (QALYs) in infants experiencing their first RSV season. Methods The impact of administering nirsevimab across all infant populations compared to palivizumab in the high-risk palivizumab-eligible population was assessed via a static decision-analytic model specified for a UK birth cohort experiencing their first RSV season. The RSV-related health events of interest included primary care (PC), accident and emergency (A&E) visits, hospitalizations [including hospitalizations alone and those resulting in intensive care unit (ICU) admissions], recurrent wheezing in infants who were previously hospitalized, and all-cause LRTD hospitalizations. Results Under the current standard of practice (SoP), RSV was estimated to result in 329,425 RSV LRTDs annually, including 24,381 hospitalizations and ICU admissions, representing £117.8 million (2024 GBP) in costs. Comparatively, universal immunization of all infants with nirsevimab could avoid 198,886 RSV LRTDs, including 16,657 hospitalizations and ICU admissions, resulting in savings of £77.2 million in RSV treatment costs. Considering the impact on all-cause LRTD of a universal immunization strategy, nirsevimab could be valued between £243 and £274, assuming willingness-to-pay (WTP) thresholds of £20,000 and £30,000 per QALY saved, respectively. Conclusions This analysis demonstrated that the health and economic burden of RSV would be substantially reduced in all infants experiencing their first RSV season in the UK (including term, preterm, and palivizumab-eligible infants) as a result of a universal immunization strategy with nirsevimab.


  • Open Access

    2640. Estimated Additional Burden Averted from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States: 2017-2020 Seasons

    by Ian McGovern, Alexandra Taylor, Aditya Sardesai, Hector Toro-Diaz, Mendel Haag

    Influenza vaccines have traditionally been produced in eggs, which can introduce egg-adaptive mutations. Cell-based influenza vaccines avoid egg-adaptive mutations, potentially improving match to circulating influenza viruses and therefore vaccine effectiveness. This study modeled the public health impact if all vaccinated people 0-64 years of age in the United States received cell-propagated inactivated quadrivalent influenza vaccine (IIV4c) compared to egg-propagated inactivated quadrivalent influenza vaccine (IIV4) across the 2017-2018 through 2019-2020 Influenza Seasons. The modeling method used by the US Centers for Disease Control and Prevention (CDC) for estimating overall burden averted due to influenza vaccination was extended to a relative vaccine effectiveness (rVE) context. The model utilized CDC data on influenza vaccine uptake, influenza incidence, influenza-related healthcare resource use and deaths. CDC estimates of absolute vaccine effectiveness (aVE) (any vaccine) were used as the aVE of IIV4. Based on previously published rVE estimates generated from the same real-world database, the rVE of IIV4c vs IIV4 was assumed to be 19.3% (95% Confidence interval: 9.5 to 28) in 2017-2018, 7.6% (6.5 to 8.6) in 2018-2019, and 17.2% (15.8 to 18.6) in 2019-2020. Base-case results were validated with deterministic (DSA) and probabilistic (PSA) sensitivity analyses. Number of Outcomes Prevented from Use of IIV4c Compared to IIV4 Among People 0-64 Years of Age: 2017-2018 Through 2019-2020 Seasons Use of IIV4c instead of IIV4 during the 2017-2020 influenza seasons in the US would have had a substantial public health impact due to a 28.5% to 49.1% increase in influenza cases prevented. Ian McGovern, MPH, CSL Seqirus: Employment|CSL Seqirus: Stocks/Bonds Alexandra Taylor, MSc, CSL Seqirus: Advisor/Consultant Aditya Sardesai, MSc, CSL Seqirus: Advisor/Consultant|Merck & Co. Inc: Grant/Research Support|Merck & Co. Inc: Grant/Research Support Hector Toro-Diaz, PhD, CSL Seqirus: Advisor/Consultant Mendel Haag, PhD, PharmD, CSL Seqirus: Stocks/Bonds

  • Open Access

    Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

    by Alexia Kieffer, Matthieu Beuvelet, Aditya Sardesai, Robert Musci, Sandra Milev, Julie Roiz, Jason K H Lee

    Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its potential impact on RSV-associated, medically attended lower respiratory tract illness (RSV-MALRTI) and associated costs. Methods: A static decision-analytic model of the US birth cohort during its first RSV season was developed to estimate nirsevimab’s impact on RSV-related health events and costs; model inputs included US-specific costs and epidemiological data. Modelled RSV-related outcomes included primary care and emergency room visits, hospitalizations including intensive care unit admission and mechanical ventilations, and RSV-related mortality. Results: Under current standard of care, RSV caused 529 915 RSV-MALRTIs and 47 281 hospitalizations annually, representing $1.2 billion (2021 US dollars [USD]) in costs. Universal immunization of all infants with nirsevimab is expected to reduce 290 174 RSV-MALRTI, 24 986 hospitalizations, and expenditures of $612 million 2021 USD. Conclusions: An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.